Skip to content

Author

V. Copeland

We have 11 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Frailty redefines the prognostic value of multimorbidity in heart failure

Multimorbidity is common and associated with adverse outcomes in heart failure (HF). However, its prognostic value across frailty states is uncertain, particularly whether comorbidities continue to stratify risk once frailty develops. To evaluate whether frailty modifies the association of multimorbidity i...

V. Copeland, B. Fishman, S. Elimelech et al. · 0 citations
Open access Oct 2026

Sex, comorbidities, and mortality in tricuspid regurgitation: Reassessing risk beyond valve severity

Severe tricuspid regurgitation (TR) is strongly associated with increased mortality, supported by robust clinical data. However, sex-related differences in the natural history and prognosis of TR remain inadequately characterized. To evaluate sex-related differences in outcomes among patients with varying...

N. Karra, L. Segev-Steinbuch, V. Copeland et al. · 0 citations
Open access Oct 2026

Frailty across the lifespan in heart failure: age-modified drivers and prognostic implications

Frailty is a multidimensional syndrome of reduced physiologic reserve associated with adverse outcomes in heart failure (HF). Whether its underlying drivers and prognostic significance differ by age remains poorly understood. To assess age-specific correlations of frailty, predictors of incident frailty, a...

V. Copeland, B. Fishman, S. Elimelech et al. · 0 citations
Open access Oct 2026

Sex-specific impact of chronic kidney disease on mortality and dialysis in heart failure with metabolic syndrome

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder defined by the overlapping burden of heart failure (HF), chronic kidney disease (CKD), diabetes, and obesity. Although sex differences in cardiovascular disease are increasingly recognized, sex-specific patterns of mortality and renal progressi...

D. Hochstein, R. Loutati, V. Copeland et al. · 0 citations
Open access Oct 2026

Improving outcomes in HFpEF with advanced CKD: temporal trends from the SHEBAHEART Registry

Patients with advanced chronic kidney disease (CKD) and heart failure (HF) are systematically underrepresented in clinical trials despite comprising a substantial proportion of real-world HF populations [1]. Whether contemporary care has translated into improved outcomes in this high-risk group particularly among...

D. Hochstein, D. Sternik, V. Copeland et al. · 0 citations
Open access Oct 2026

Adverse effect of left ventricular hypertrophy in women with heart failure

Left ventricular hypertrophy is a hallmark of adverse remodeling in heart failure (HF), yet commonly used echocardiographic measures provide limited insight into sex-specific risk. Interventricular septal (IVS) thickness is routinely measured, but its independent prognostic value and potential sex-related differe...

A. Kaplan, V. Copeland, R. Loutati et al. · 0 citations
Oct 2026

History of hypertension is associated with improved survival in patients with nonischemic etiology of heart failure and reduced ejection fraction.

BACKGROUND Hypertension (HTN) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF), yet its prognostic significance remains complex. OBJECTIVE To evaluate the association between HTN and all-cause mortality in patients with HFrEF, stratified by ischemic and nonischemic etiolog...

Daniel Zango, V. Copeland, Y. Wasserstrum et al. · 0 citations
Open access Oct 2026

Chronic kidney disease in metabolic syndrome and heart failure: elevated risk, underutilized therapies, and missed opportunities for improved outcomes

In patients with late-stage metabolic syndrome, CKD identifies a high-risk subgroup with a graded increase in mortality and dialysis risk compared with eGFR ≥60, and the heightened dialysis risk remained pronounced after accounting for competing death.

D. Hochstein, R. Loutati, V. Copeland et al. · 0 citations
Sep 2026

Calcium Channel Blockers are Safe and Beneficial in Patients with Heart Failure and Advanced Chronic Kidney Disease.

In patients with heart failure and advanced chronic kidney disease, CCBs use was associated with improved survival, supporting their potential role as a safe adjunctive therapy for blood pressure control in this high-risk population.

V. Copeland, A. Milwidsky, S. Elimeleh et al. · 0 citations
Open access Sep 2026

Point-of-care echocardiography screening for hypertrophic cardiomyopathy using automated deep-learning analysis

Abstract Aims Hypertrophic cardiomyopathy (HCM) remains underdiagnosed due to limited access to expert imaging. We developed and validated a deep-learning (DL)-based echocardiographic model adaptable to point-of-care ultrasound (POCUS) for scalable HCM screening. Methods and results We retrospectively analysed 134 956...

N. Karra, Y. Klempfner, V. Copeland et al. · 0 citations
Aug 2026

Frailty Attenuates the Prognostic Value of Multimorbidity in Heart Failure - Insights From the Largest Tertiary Center in the Middle East.

Frailty fundamentally attenuates risk in HF, while multimorbidity stratifies prognosis only when physiological reserve is preserved, while multimorbidity stratifies prognosis only when physiological reserve is preserved.

V. Copeland, Boris Fishman, S. Elimeleh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.